NATHBIOGEN2023-04-012023-06-30 NATHBIOGEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member NATHBIOGEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member NATHBIOGEN2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 537291 NATHBIOGEN NA Nath Bio-Genes (India) Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-08-02 INR Lakhs First quarter 15:30:00 17:25:00 2023-08-10 2023-08-10 Not applicable Single segment SEED CULTIVATION 2023-04-01 2023-06-30 Unaudited Standalone 2352816000.00 1170000.00 2353986000.00 694248000.00 19676000.00 513625000.00 71253000.00 27645000.00 7600000.00 683706000.00 2017753000.00 336233000.00 0.00 336233000.00 2201000.00 0.00 2201000.00 0.00 334032000.00 0.00 0.00 0.00 0.00 334032000.00 0.00 334032000.00 0.00 0.00 190040000.00 10 17.58 17.58 0.00 0.00 17.58 17.58 AVTotal Comprehensive Income for the period (XIII + XIV) XVI Paid Up Equity Share Capital (Face Value Rs. 10/- each) 3340.32 161.12 3075.64 3340.32 3075.64 1900 40 1900.40 58775,34 1900.40 55372.18 17.58 55372.18 16.18 3518.57 1900 40 18.51 55435.02 FOR NATH BIO-GENES (INDIA) LTD SATISH KAGLIWAL MANAGING DIRECTOR DIN 00119601 16.18 1900.40 0.85 55435.02 17.58 58775.34 1900.40 Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted NOTES: (1) The financial results were reviewed by the Audit Committee in meeting held on 09 August 2023 and were thereafter approved by the Board of Directors at its meeting held on 10 August 2023. (2) The company is dealing in one major product segment, i.e. Seed Cultivation. (3) Investor complaints - Opening Balance - 0. Received and Solved - 1, Closing Balance - 0 (4) The figures have been regrouped/rearranged where ever necessary. Other Expenses 55159000.00 Selling and Distribution Expenses 628547000.00 0.00 0.00